logo.jpg
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021 09:00 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc., (“Vallon” or the “Company”), a biopharmaceutical company focused on the development of novel drugs for CNS disorders,...
Logo 1.png
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05, 2021 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
The Greater Cannabis Company Announces Launch of Bob Ross Beauty and Cosmetics Products
November 23, 2020 10:10 ET | The Greater Cannabis Company, Inc.
Initial products to launch in Party City and online through e-tailer network for holiday season Baltimore, MD, Nov. 23, 2020 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the...
Logo.jpg
Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds
November 12, 2020 04:27 ET | Biofrontera AG
Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00%...
Logo.png
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
October 02, 2020 06:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that...
Logo 1.png
Aeterna Zentaris Provides Corporate Update
September 16, 2020 08:05 ET | Aeterna Zentaris Inc
– Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to...
Logo.jpg
Biofrontera AG plans mediation to resolve (legal) disputes
September 11, 2020 07:33 ET | Biofrontera AG
Leverkusen, Germany, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical...
Logo.jpg
Biofrontera AG to participate in two upcoming conferences
September 09, 2020 08:00 ET | Biofrontera AG
Leverkusen, Germany, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be...
Logo.jpg
Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021
August 20, 2020 13:00 ET | Biofrontera AG
Leverkusen, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) -- On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified...
Logo.jpg
Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
August 18, 2020 05:00 ET | Biofrontera AG
Leverkusen, Germany, Aug. 18, 2020 (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,638,150...